Powerful Biology
Accelerating the
Future of Medicine

The future of advanced medicines relies upon deeper access to in vivo biology to create durable, curative impacts on disease. Our systems, which drive convergence of dynamic proteomics and single cell biology for the first time, are creating this deeper connection to accelerate curative medicines.

Introducing IsoSpark

Accelerate immune medicine across research areas & high-impact applications.

Introducing Duomic

Capture transcriptomic + functional proteomics from the same single cell.

Bridging the Gap to Accelerate Medicine

Isoplexis captures proteomics reflecting in vivo biology with walk-away automation to cut therapeutic development timelines and add efficacy


Proteins Reflecting & Predicting
in vivo Biology


High MultiPlex from Single Cells & Bulk Captures Complexity


Time Saved with
Analytics Automation

Single-Cell Functional Proteomics Hub

Accelerate your therapeutics and biomarkers
with an all-in-one integrated system

Our Solutions

The Products Driving Our Superpowered Biology

Better Biomarkers,
Accelerated Development
Functional Immune

Accelerate the ability to clarify lead candidate choice and durable biomarkers using the proteomic secretome from each single cell to accelerate path to the clinic and higher efficacy with targeted immune therapies.

Accelerated Discovery
and Targeting
Intracellular Signaling

Identify adaptive phosphoproteomic signaling networks from rare subsets of single tumor and other cell types, leveraging single cell proteomics to treat the entire set of signaling pathways concurrently, and eliminate resistance and metastases.

Sample to Insights,
for Any Lab
High-plex Walk-Away

For the first time, unleash walk-away multiplexed proteomics in very low sample volumes, with an analytics suite that saves resources and time while delivering key omic insights.


Superpowered Biology Built on a Strong Foundation

Our Unique Biology

Proteomics, Reimagined to uniquely detect our most powerful cells.

Explore Our Biology

Instrument Virtual Demo
Virtual Demo

The entire ELISA proteomics workflow, sample to answer.

Take the Virtual Tour

Data Visualization Tour

IsoSpeak Software: Same day visualizations and insights.

Tour the Visualizations

Areas of Interest

See how we can shift the paradigms in your programs


Enabling a New Era of Precision Medicine

Latest Customer Stories View Blog

Blog Image_11.5.21_ 1080 x 608_
eBook: Understanding Immune Cell Function in Cancer
Webinar Now Available – Sharpening a Double-Edged Sword: Bispecific CAR-T Cancer Therapies
Expert Panel Discussion: Advances in Cell and Immunotherapies in Treating Cancer

Featured Content

Trusted Worldwide

We innovated the only way to measure the true function of each cell and identify the rare subsets of superpowered cells driving response.

As a cancer research center with a key focus on CAR-T and other cell therapies, we feel that IsoPlexis will enable us to better characterize response and potentially predict whether cancer patients will respond to CAR-T therapy before treatment.
Christine Brown

City of Hope

The ability of the IsoLight to provide detailed analyses from very few cells is key, given that we are limited to small sample quantities of blood.
Petter Brodin, MD PHD

Associate Professor of Immunology at Karolinska Institute

Quality assays are mainly descriptive with some objective parameters like cytokine production, cytotoxicity, and proliferation. Only recently, with PSI… can we start to differentiate products.
Marco L Davila

Moffitt Cancer Center

We see potential in utilizing IsoPlexis’ single-cell system to help provide deeper resolution into the functional impacts of our therapeutics… This collaboration will enable us to apply the sensitivity of this solution to further our understanding of patient-specific responses to our immune therapies.
Jon Zalevsky

Chief Scientific Officer, Nektar Therapeutics

Through this research, we were able to highlight the important role a functionally versatile subpopulation of CAR-T cells may play in the fight against cancer. This could lead to new methods to optimize T-cell products.
Adrian Bot, MD

Vice President, Translation Sciences, Kite

Current assays that rely on a single-plex ELISA or even multiparametric flow cytometry don’t give you the level of resolution that the IsoPlexis platform can provide.
John Rossi

Director of Translational Sciences at Kite

Spark the Next Breakthrough